Elekta highlights ASTRO data showing 37.4% two-year survival in localized pancreatic cancer
Company said the results were presented at ASTRO 2026 on its Unity MR-Linac and support broader uptake of MR-guided adaptive radiotherapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.